Zhongda Enterprise International (03839.HK) net profit for 2025 is $32.1 million, a year-over-year increase of approximately 186.6%

NightAirdropper · 2026-02-26T09:49:22+00:00

Zhongda Enterprise International's annual performance up to December 31, 2025, saw revenue increase by 74.1% to $536 million, mainly driven by biotechnology business and pharmaceutical product sales. Gross profit margin slightly declined to 14.4%, and attributable profit to shareholders rose to $32.1 million.

NightAirdropper

2026-02-26 09:49:22

Abstract generation in progress

Grandhope Biotech International (03839.HK) announced its full-year results for the year ending December 31, 2025. For the year ending December 31, 2025, the group’s revenue increased by 74.1% to $535.9 million (2024: $37.7 million). As mentioned above, the group’s revenue comes from its consolidated biotech business. The significant increase in revenue reflects our successful implementation and ongoing execution of key strategies to develop major client sales. Most of the revenue growth was driven by the growth of auto-immune drug products. The overall gross profit margin decreased from 15.9% in 2024 to 14.4% in 2025. The company’s profit attributable to shareholders in 2025 was $32.1 million, compared to $11.2 million in 2024. The profit increase was mainly due to the significant growth of the group’s biotech business.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes